DUBLIN--(BUSINESS WIRE)--The "Sepsis Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The sepsis diagnostics market was valued at USD 550 million in 2020 and is expected to reach USD 975 million in 2026 by registering the CAGR of 9.8% during the forecast period.
Companies Mentioned
- Abbott Laboratories Inc.
- Axis-Shield Diagnostics Ltd.
- Becton, Dickinson, and Company
- BioMerieux SA
- Bruker Corporation
- Cube Dx GmbH
- Danaher Corporation
- EKF Diagnostics
- F. Hoffmann-LA Roche Ltd
- Immunexpress Inc.
- Diasorin
- Response Biomedical Corp.
- Sysmex Corporation
- T2 Biosystems, Inc.
- Thermo Fisher Scientific
Key Market Trends
Molecular Diagnostics Segment, by Technology, is Expected to grow the Fastest over the Forecast Period.
As per the Canadian Medical Association, in December 2020, the most common complications associated with COVID-19 were pneumonia, respiratory failure, kidney failure, and sepsis or systemic inflammation, consistent with other studies. The absolute risk of someone with COVID-19 having sepsis was estimated to be approximately 10.4%. Researchers are attempting to develop a molecular diagnostic that can detect the COVID-19 and sepsis, as well as discriminate between the two. In November 2020, the Hellenic Institute for the Study of Sepsis and, in part by Sanmina Corporation, funded a study and developed a novel optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of the market.
Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Moreover, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis diagnostics. Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods. The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method.
However, the cost of molecular diagnostics has remained very high, as compared to conventional procedures, which restricts its market growth. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For instance, in April 2019, GenMark Diagnostics, Inc. received the FDA clearance for its new panel assay, developed to detect gram-negative bacteria causing sepsis. The well-established healthcare infrastructure with high adoption of advanced diagnostic technologies and a rising awareness for early disease diagnosis are expected to drive the market's growth.
North America is Expected to Hold Largest Share of the Market
COVID-19 has increased the overall risk of sepsis among the global population. The Global Sepsis Alliance stated that COVID-19 could cause sepsis, causing an overwhelming and life-threatening physiological response to an infection that can lead to organ damage and death. In the United States, one in three COVID-19 patients who dies in a hospital dies of sepsis. Owing to this high susceptibility to the disease in this region, the market is expected to grow in the future.
North America is found to hold a major share of the sepsis diagnostics market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the CDC statistics in 2018, sepsis affects more than a million Americans every year and leads to 15% to 30% deaths in the United States. Furthermore, the number of sepsis cases is rising every year in the country due to factors, such as the rise in the geriatric population, infections that are incurable by antibiotics, and higher risks of the disease among people who have undergone an organ transplant.
The National Institutes of Health supports many studies that are focused on sepsis, which evaluate various potential treatments for the disease. CDC launched the 'Get Ahead of Sepsis', which is an educational initiative to protect Americans from the effect of sepsis. This initiative calls on healthcare professionals to educate patients, prevent infections, identify and diagnose sepsis at an early stage, and start sepsis treatment fast. Emerging technologies linked with an enhanced understanding of the immature and developing neonatal immune system responses to early infection provide an opportunity to develop critically needed biomarkers to improve early identification in this high-risk population.
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Sepsis
4.2.2 Growing Incidence of Hospital-acquired Infections
4.2.3 Rise in the Number of Sepsis Procedures and Increase in Funding for Sepsis-related Research Activities
4.3 Market Restraints
4.3.1 High Cost of Automated Diagnostic Instruments
4.3.2 Lack of Well-established Reimbursement Policies for Sepsis
4.4 Porter's Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Technology
5.2 By Product
5.3 By Diagnostic Method
5.4 By Pathogen
5.5 Geography
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/6gp6ns
